Biocon Announces Merger of Biologics Unit in $5.5 Billion Deal
The Indian biopharmaceutical giant Biocon has announced a major restructuring step by merging its well-known subsidiary, Biocon Biologics, into a fully owned entity valued at 5.5 billion dollars. The announcement has created strong interest in the healthcare and pharmaceutical market, since this move marks one of the most important corporate steps taken by Biocon in recent years.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
